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In Brief
Talbot et al. provide mechanistic insights
into how neuro-immune interplay
amplifies type 2 allergic airway
inflammation. Based on this, they
propose a new treatment strategy for
asthma, using charged sodium channel
blockers to selectively silence sensory
neurons in the lung.
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Lung nociceptors initiate cough and bronchocon-
striction. To elucidate if these fibers also contribute
to allergic airway inflammation, we stimulated lung
nociceptors with capsaicin and observed increased
neuropeptide release and immune cell infiltration.
In contrast, ablating Nav1.8+ sensory neurons or
silencing themwith QX-314, a charged sodium chan-
nel inhibitor that enters via large-pore ion channels to
specifically block nociceptors, substantially reduced
ovalbumin- or house-dust-mite-induced airway in-
flammation and bronchial hyperresponsiveness. We
also discovered that IL-5, a cytokine produced
by activated immune cells, acts directly on nocicep-
tors to induce the release of vasoactive intestinal
peptide (VIP). VIP then stimulates CD4+ and resident
innate lymphoid type 2 cells, creating an inflamma-
tory signaling loop that promotes allergic inflamma-
tion. Our results indicate that nociceptors amplify
pathological adaptive immune responses and that
silencing these neurons with QX-314 interrupts this
neuro-immune interplay, revealing a potential new
therapeutic strategy for asthma.
INTRODUCTION
Asthma is an inflammatory airway disease caused by environ-
mental (allergens, air pollution, cold, and smoking) and genetic
interactions (Martinez, 2007). The disease affects 7%–10% of
the world’s population, causes 250,000 deaths annually (Akin-
bami, 2006), and its prevalence is increasing (Ramsey and Cele-
do´n, 2005). Asthma symptoms include wheezing, coughing,
chest tightness, and shortness of breath, caused by increased
airway hyperresponsiveness, inflammation, mucus hypersecre-
tion, and structural remodeling (Locksley, 2010). Histopathologyshows goblet cell metaplasia, thickened basement membranes,
increased airway smooth muscle, and inflammatory cell infiltra-
tion (Locksley, 2010). Immune cells, particularly innate lymphoid
type 2 cells (ILC2), T helper 2 (Th2) cells, and eosinophils, are
central to the pathological airway transformation. Inhaled aller-
gens, such as house dust mites (HDMs), viruses, or bacteria,
are sensed mainly by dendritic cells in the lung mucosa, which
promote precursor Th cell differentiation into Th2 cells. These,
along with ILC2 cells, initiate an inflammatory response that in-
cludes recruitment and activation by cytokines of immune
effector cells, with eosinophils contributing to bronchoconstric-
tion, microvascular permeability, and airway remodeling (Kumar
et al., 2005; Locksley, 2010).
The lung is densely innervated by sensory fibers, most of
which expressmarkers of nociceptors, including the transient re-
ceptor potential (TRP) channels TRPV1 and TRPA1 (Ni et al.,
2006). Airway nociceptors respond to chemical, mechanical, or
thermal stimuli to initiate essential protective airway reflexes,
such as coughing (Canning et al., 2006). Asthmatic patients
have a denser network of these fibers around small airways
(Barnes, 1996; Myers et al., 2002) and a reduced activation
threshold in response to airborne irritants (Canning and Spina,
2009). Patients also display elevated neuropeptide levels in
bronchoalveolar lavage fluids (BALFs) (Lilly et al., 1995). These
features indicate changes in and excess activity of peptidergic
sensory fibers (Patterson et al., 2007). The large-pore cation
channels TRPV1 and TRPA1 are activated by exogenous chem-
ical irritants, such as cigarette smoke (Kanezaki et al., 2012), and
also directly and indirectly via GPCR- and receptor tyrosine ki-
nase coupling by many endogenous ligands generated during
inflammation, including protons, lipids, endogenous cannabi-
noids, bradykinin, and NGF (Szallasi et al., 2007). Stimulation
of nociceptor peripheral terminals results in calcium-mediated
vesicular release of neuropeptides, like substance P and calci-
tonin gene-related peptide (CGRP), to generate neurogenic
inflammation, which is characterized by increased vascular
permeability and vasodilation. This is amplified and spreads by
the antidromic reflex, where the sensory input in one branch of
a sensory neuron initiates an action potential back down aNeuron 87, 341–354, July 15, 2015 ª2015 Elsevier Inc. 341
connecting branch to its peripheral terminal (Chiu et al., 2012).
Nociceptors may contribute to airway disease both by their ca-
pacity to produce bronchoconstriction (Tra¨nkner et al., 2014)
and local neurogenic inflammation (Caceres et al., 2009; Hox
et al., 2013). Supporting involvement of sensory fibers in key
aspects of type 2 inflammation, genetic knockout (KO), or phar-
macological antagonism of the TRPA1 channel reduced inflam-
mation in a mouse model of allergic airway disease (Caceres
et al., 2009), while ablation of TRPV1 afferents blocked bronchial
hyperresponsiveness (Tra¨nkner et al., 2014). However, exactly
how sensory neurons and immune cells cooperate to amplify
immunopathology and direct various types of inflammation is un-
known (Chiu et al., 2013; Liu et al., 2014; Nussbaum et al., 2013;
Riol-Blanco et al., 2014; Wilson et al., 2013).
We have investigated the contribution of lung nociceptor
neurons to the generation and resolution of allergic airway
inflammation by asking if global ablation of all nociceptor neu-
rons (NaV1.8-expressing neurons) attenuates allergen-induced
immune responses. We also temporarily silenced nociceptors
using inhaled permanently charged quaternary derivatives of
sodium channel blockers (Binshtok et al., 2007). The charge of
these quaternary compounds prevents their diffusion through
neuronal membranes, making them ineffective as local anes-
thetics. However, their small size enables them to permeate
into cells through activated large-pore channels, including
TRPV1 (Binshtok et al., 2007) and TRPA1 (Lennertz et al.,
2012). A combination of a TRP channel opener and the charged
sodium blocker QX-314 produces prolonged (>9 hr) peripheral
nociceptor silencing and a pain- or itch- specific local blockade
(Binshtok et al., 2007; Brenneis et al., 2013; Roberson et al.,
2013). This strategy enabled us to determine the consequences
of blocking lung nociceptor activity on established allergic
inflammation. We found that sensory neurons, in part through
the vasoactive intestinal peptide (VIP)-VPAC2 axis, drive CD4+
and ILC2 cell production of cytokines including IL-5, and recipro-
cally that IL-5 activates sensory neurons. Our results indicate
that nociceptors play a major role in amplifying adaptive immune
responses in the lung, and they show that local pharmacological
silencing of nociceptors interrupts the pro-inflammatory
signaling loop between neurons and immune cells to enhance
allergic airway inflammation resolution.
RESULTS
Nociceptor Activation and Allergic Airway Inflammation
Allergic inflammation and bronchial hyperresponsiveness can be
induced in mice by an initial sensitization to an allergen, in this
case ovalbumin (OVA) (intraperitoneally [i.p.], days 0 and 7), fol-
lowed by inhaled OVA challenges (days 14–17) (Figure 1A). To
investigate if sensory fibers play a role in allergic airway inflam-
mation, we first performed lung nociceptor gain-of-function ex-
periments in vivo. Mice were treated with intranasal instilled
capsaicin, a selective TRPV1 agonist (Szallasi et al., 2007), and
24 hr later BALF was immunophenotyped. In naive mice (no
OVA exposure), capsaicin treatment increased CD45+ cells
(marker of all immune cells) (Figure 1B). In OVA-treated mice,
capsaicin administration on day 18 (the day after completing
OVA challenges and time of maximal inflammation) further342 Neuron 87, 341–354, July 15, 2015 ª2015 Elsevier Inc.increased the already elevated levels of CD45+ cells (Figure 1B).
These included eosinophils (Figure 1C), macrophages (Fig-
ure 1D), and lymphocytes (Figure 1E). The pro-inflammatory
effect of capsaicin also was observed in lungs of lymphocyte re-
porter mice (LCK+/eGFP+/; Figures 1F and 1G). We conclude
that exogenous activation of lung nociceptors increases airway
leukocytes. The larger effect in OVA-challenged mice than naive
mice implies that factors released by nociceptors in inflamed
lung augment immune cell recruitment.
Nociceptor Ablation and Allergic Airway Inflammation
We next used targeted diphtheria toxin-based cell ablation (Pal-
miter et al., 1987) to explore if nociceptor neurons are required
for lung inflammation in the OVA mouse model. NaV1.8 is a
TTX-resistant voltage-gated sodium channel expressed by noci-
ceptors, including those in the nodose ganglion (Muroi and
Undem, 2014) and themajority of nodose ganglion lung afferents
(Kwong et al., 2008). NaV1.8-Cre
+/DTA+/mice are devoid of all
NaV1.8-expressing nociceptors (Stirling et al., 2005) and have no
response to noxious heat, mechanical stimuli, or capsaicin (Chiu
et al., 2013). In WT mice and NaV1.8-Cre
+/DTA/ littermate
control mice (with intact nociceptors), numbers of CD45+ cells,
including eosinophils and lymphocytes, increased substantially
in BALFs obtained on protocol day 21 (4 days after the last
inhaled OVA challenge) (Figures 2A–2D). In contrast, OVA-
exposed NaV1.8-Cre
+/DTA+/ mice (with ablated nociceptors)
showed significantly dampened immune cell infiltration on day
21, with fewer eosinophils, macrophages, and lymphocytes (Fig-
ures 2A–2D).
Silencing Airway Nociceptors in Non-inflamed Lungs
Since ablating nociceptors during development might conceiv-
ably cause compensatory changes in the lung and immune sys-
tem, we shifted to a strategy to temporarily silence afferents in
the adult lung using large-pore ion channels as a drug entry
port for charged sodium channel blockers to produce targeted
action potential blockade (Binshtok et al., 2007; Brenneis et al.,
2013). We first assessed the efficiency of sensory neuron
silencing using QX-314, a permanently charged quaternary de-
rivative of lidocaine, in reversing neuropeptide release from noci-
ceptors and consequent vascular leakage in the lung. Activating
lung nociceptors in naive mice with capsaicin (1 mmol, 20 ml
instilled intranasally) induced significant increases in CGRP
levels in BALFs collected 60min later (Figures 3A–3D). Pre-treat-
ment with QX-314 (100 mM) by inhaled nebulizer 1 hr prior to the
capsaicin (when no large-pore channels were activated) failed to
alter subsequent capsaicin-induced increases in the neuropep-
tide, showing that, when administered by itself in the non-in-
flamed lung, QX-314 fails to block nociceptors, an expected
result since there is no portal for entry into nociceptors and it is
ineffective when administered extracellularly (Binshtok et al.,
2007; Figure 3A). However, when administered just after capsa-
icin administration, which opens TRPV1 channels, QX-314
blocked CGRP release into BALF (Figure 3B). Co-administration
of QX-314 with capsaicin also blocked development of plasma
extravasation in the lung, a measure of capillary permeability
due to neuropeptide release (Figure 3C). These data show that,
when large-pore channels are exogenously activated by TRP
Figure 1. Nociceptor Activation Promotes Airway Inflammation
(A) Inflammation induced in mice following i.p. allergen (OVA) sensitization (days 0 and 7, with AlOH) and inhaled challenge (days 14–17). Drugs/vehicle was
administered at peak of OVA-induced inflammation (day 18) and impact was assessed on day 21.
(B–E) Capsaicin (B–E; 1 mmol, red bar) or vehicle (white bar) instilled (intranasally) on day 17 after vehicle or OVA challenge (24 hr prior to BALF measurement).
Capsaicin increased airway CD45+ (total immune) (B), eosinophil (C), macrophage (D), and lymphocyte (E) cell counts.
(F and G) T cell influx (green, LCK-Cre+/eGFP+/) in control lungs following vehicle (F) or capsaicin (G; 1 mmol) instillation is shown. Scale bar, 10 mm. Mean ±
SEM; two-tailed unpaired Student’s t test (n = 6–10 animals/group, two cohorts).channel agonists, QX-314 can enter into lung nociceptors and
inhibit them.
Silencing Airway Nociceptors in Inflamed Lungs
Reduced OVA-induced allergic airway inflammation in TRPA1-
KO mice (Caceres et al., 2009) and following TRPV1-small
interfering RNA (siRNA) knockdown (Mabalirajan et al., 2013;
Rehman et al., 2013) indicates activation of these channels by
endogenous ligands during allergic inflammation, providing theopportunity to target QX-314 into nociceptors in inflamed lungs
without the need for administration of an exogenous TRP chan-
nel agonist. When QX-314 was administered 60 min prior to a
capsaicin challenge to OVA-challenged mice on day 18, at the
height of inflammation, capsaicin-evoked neuropeptide release
was, unlike the situation in naive mice, markedly decreased (Fig-
ure 3D), showing that QX-314 treatment by itself in OVA-
exposed mice locally blocked nociceptors. To further assess
afferent silencing, intranasal capsaicin (500 nmol) was instilledNeuron 87, 341–354, July 15, 2015 ª2015 Elsevier Inc. 343
Figure 2. Lung Sensory Neuron Ablation Reduces Airway Allergic Inflammation
(A–D) Four days after last aerosol challenge (day 21), OVA-exposed mice developed CD45+ cell count increases in BALF (A), including eosinophils (B) and
lymphocytes (D), but not macrophages (C). Ablation of NaV1.8- (NaV1.8
+/DTA+/, orange squares; A–D) expressing sensory neurons significantly decreased
these levels. Mean ± SEM; two-tailed unpaired Student’s t test (n = 4–12 animals/group, one to two cohorts).in OVA-challenged mice, and nodose ganglion neuron activation
was measured by phospho-ERK (p-ERK) immuno-labeling.
When OVA-challenged mice were pre-exposed to QX-314
(100 mM) 1 day prior to p-ERKmeasurements, fewer lung afferent
neurons, identified by retrograde DiI-label (Figure S1), were
p-ERK positive than in vehicle-treated mice (18.5% versus
86.5% [Figures S1A–S1D]), demonstrating that inhaled QX-314
silences lung nociceptors in OVA-treated mice. Activation of
lung nociceptor TRP channels, either by capsaicin in naive ani-
mals or by endogenous ligands during allergic inflammation, per-
mits sufficient QX-314 entry to block local nociceptor activity
(Figures S1E–S1G).
Nociceptor Silencing and Allergic Airway Inflammation
Single 100-mM treatment with QX-314 on day 18, after OVA inha-
lation challenges on days 14–17 in OVA-sensitized mice, sub-
stantially reduced the immune cell infiltration normally seen on
day 21, with decreased BALF CD45+ cells (total immune cells)
and decreased eosinophils, macrophages, and lymphocytes
(Figures 4A–4D). Similar results were seen in H&E-stained lung
tissue (Figures 4E–4G). The QX-314 effects were independent
of sex, age (8 versus 16 weeks), and strain (C57Bl/6 versus
BALB/c) (data not shown). In addition, this treatment decreased
by 1.75-fold the airway basement membrane thickening (Fig-
ure 4H). We also tested if sensory neuron silencing reversed
type 2 inflammation in the clinically relevant HDM model (John-
son et al., 2004). Briefly, 8-week-old male BALB/c mice were
sensitized with HDM (days 1–5) and challenged on days 8–10.
On day 15, HDM-challenged mice showed increased BALF
CD45+ cells (Figure 4I) and lymphocytes (Figure 4J), both of
which were reduced by QX-314 (100 mM, day 12) treatment. To
establish if this was general to all types of allergic inflammation,
we analyzed the impact of silencing in a type 1-skewed allergic
airway inflammation model. Here, instead of sensitizing mice
with aluminum hydroxide and OVA as in all the experiments
above, which produces a Th2-skewed inflammation (Bogaert
et al., 2011), mice were sensitized with a mixture of complete
Freund’s adjuvant (CFA) and OVA (Bogaert et al., 2011), which
models non-eosinophilic Th1-skewed asthma. These mice had
a 2-fold increase in the Th1/Th2 ratio (defined as CD4+IFNg+
cells/CD4+IL4+ cells) compared to AlOH/OVA-sensitized mice344 Neuron 87, 341–354, July 15, 2015 ª2015 Elsevier Inc.(Figure 4K). QX-314 failed to impact levels of CD45+ cells (Fig-
ure 4L), eosinophils, macrophages, and lymphocytes on day
21 in this model (data not shown). Sensory neuron effects on
inflammation are context dependent and contribute to type 2
models of allergic airway inflammation, but not a type 1 model.
Inhaled lidocaine, a short-acting sodium channel blocker, has
anti-inflammatory effects on murine asthma models (Serra et al.,
2012) and in patients (Weiss and Patwardhan, 1977), but directly
suppresses immune cells (Serra et al., 2012). We therefore
investigated if QX-314 has direct effects on immune cells. QX-
314 had no impact on in vitro survival, chemotaxis, and activa-
tion of lung macrophages and eosinophils (data not shown), and
exposure to QX-314 (up to 1 mM) had no effect on Th0, Th1, and
Th2 cell proliferation or cytokine production in vitro (data not
shown). We conclude that the immune-suppressing actions of
QX-314 are due to nociceptor silencing. The anti-inflammatory
effect of nociceptor silencing with QX-314 was replicated with
a chemically distinct sodium channel blocker, a permanently
charged derivative of mexiletine, N-methyl-mexiletine (NMM).
When NMM was administered by nebulizer (on day 18) to
OVA-treated mice, BALF-harvested immune cell counts were
significantly reduced (Figure S2), albeit with less potency than
QX-314. The same dose of uncharged mexiletine failed to
resolve the OVA-mediated allergic airway inflammation (Fig-
ure S2). Thus, the ability of charged compounds to penetrate
into nociceptors through activated large-pore ion channels
enables the blockade of sodium channels for longer periods,
and this is critical to how silencing sensory neurons reduces
inflammation.
We next examined the effect of sensory neuron silencing on
bronchial hyperresponsiveness. Both genetic ablation of lung
afferent neurons (data not shown) and QX-314 silencing on day
18 reversed OVA-mediated bronchial hyperresponsiveness, as
measured on day 21 by ED200RL (Figure 4M), lung elastance (Fig-
ure 4N), and resistance (Figure 4O). Specifically, the dose of
methacholine (MCh) required to produce a 200% increase in
RL (i.e., log ED200RL) decreased significantly (p < 0.001) from
6.38 ± 0.74 in control mice to 0.79 ± 0.06 after OVA challenge,
while QX-314 increased by 3-fold the log ED200RL values in
OVA-challenged mice (Figure 4M). NMM also reduced airway
hyperresponsiveness (data not shown).
Figure 3. Airway Sensory Neuron Silencing with QX-314 Abolishes Capsaicin-Induced Peptide Release and Vascular Leak
(A and B) To assess nociceptor-mediated peptide release, capsaicin (1 mmol, intranasally) was administered to naivemice. BALF CGRP levels were increased 1 hr
following the capsaicin challenge (A and B). QX-314 (100 mM) treatment 1 hr prior to the capsaicin did not alter capsaicin-induced CGRP levels (A), but QX-314
(100 mM), when administered immediately after the capsaicin, blocked the CGRP rise (B) (n = 4–15 animals/group, two to three cohorts).
(C and D) Reduction in vascular leak (C) following co-administration of capsaicin (1 mmol) with QX-314 (100 mM) (n = 4–5 animals/group, one cohort). BALF CGRP
levels increased following capsaicin (1 mmol) instillation in OVA-challenged mice (D), and this was blocked by QX-314 pre-treatment 1 hr before (100 mM). Mean ±
SEM; two-tailed unpaired Student’s t test (n = 5–12 animals/group, two cohorts).To functionally explore the consequences of airway hyperres-
ponsiveness in mice, we measured daily voluntary wheel
running. Individual animals were followed over the course of
the allergen protocol (Figure 1A) and their daily level of voluntary
exercise (1 hr, dark, 21:00–1:00 hr) was analyzed. At the
peak of inflammation (day 18), mice showed a significant
decrease in travel distance 25% compared to their pre-
challenge period (day 13) (Figure 4P), and this was matched
by an equivalent decrease in exercise duration. Voluntary wheel
running distance was rescued by QX-314 treatment, measured
24 hr later (Figure 4P). Local silencing of lung nociceptors by a
single exposure to a charged sodium channel blocker at the
peak of allergen-induced inflammation reduced two cardinal
features of allergic asthma: immune infiltration and bronchial
hyperresponsiveness.
IL-5 Activates Lung Nociceptors
Our data suggest that nociceptors are activated during exposure
to allergens in sensitized animals, but the mechanisms respon-
sible are unknown. Skin nociceptors are activated by the cyto-
kine IL-1b (Binshtok et al., 2008), and we hypothesized that
similar signaling could occur during allergic airway inflammation.
To look for candidates, we asked if silencing lung nociceptors
with QX-314 reduced BALF levels of cytokines, and we discov-
ered decreased IL-5 (Figure 5A), eotaxin-2, IL-4, IL-9, IL-10,
IL-13, IP-10, MCP-1, TNF-a, and TARC, but not IL-17, IL-23,
IL-27, IL-28b, INF-g, and RANTES (Table S1). Transcript profiling
of the naive nodose ganglion revealed that lung NaV1.8
+ noci-
ceptors express receptors for some of these cytokines, including
IL-33R, INFg-R, IL-4R, IL-9R, and IL-5R (Figure 5B). We there-
fore explored if eotaxin-2, IL-13, and IL-5 could activate cultured
nodose neurons, using calcium imaging of neurons from control,
OVA-sensitized (day 13) and OVA-sensitized and -challenged
(day 21) mice, and we observed that the latter condition
produced maximal responses (data not shown) so we choseto perform subsequent experiments on neurons from OVA-
challenged mice. Exposing neurons to eotaxin-2 or IL-13 at
concentrations up to 10 mg/ml produced small concentration-
dependent calcium increases in a few neurons (for IL-13, 3/469
KCL+ cells, 0.6%; and eotaxin-2, 26/403 KCL+ cells, 6.45%).
However, larger responses in more neurons were observed for
IL-5 (150/788 KCL+ cells, 19.04%) (Figure 5C).
IL-5, along with IL-13, is a major effector cytokine in asthma,
implicated in airway inflammation, hyperresponsiveness, and re-
modeling, as well as mucus metaplasia (Ortega et al., 2014). To
characterize nodose neurons that responded to IL-5, we
exposed them to different TRP channel ligands and found that
55% (42/78) of IL-5-responsive cells also responded to capsa-
icin and 41% (32/78) to AITC (Figure 5D), while 55%of capsaicin-
and 100% of AITC-responsive cells were IL-5 responsive (data
not shown). IL-5-responsive nodose ganglion neurons were pre-
dominantly of small and medium sizes (Figure 5E). Only 1.3% of
cultured nodose ganglion from NaV1.8-ablated mice responded
to IL-5 in comparison to 25% in littermate controls (Figure 5F).
Removing extracellular calcium eliminated the IL-5 signal (Fig-
ure 5G), suggesting flux through membrane-bound channels.
Whole-cell patch clamp recordings in current-clamp mode
from small cells (capacitance <45 pF) that had responded to
IL-5 by calcium imaging showed that IL-5 perfusion (1 mg/ml) de-
polarized the cells by 6 mV (Figures 5H and 5I; n = 12 cells), an
effect that was reversible after extensive washout (more than
20 min). Before IL-5 perfusion, cells had a stable resting mem-
brane potential (RMP) with no spontaneous action potential
firing; however, occasional spontaneous spiking was observed
following IL-5 treatment (2/12 patched cells). The current needed
to trigger an action potential (rheobase) was smaller when IL-5
was present (Figures 5J and 5K; n = 7 cells), but no difference
in spiking frequency during a ramp current was observed (data
not shown). We conclude that nociceptors can be directly acti-
vated by IL-5.Neuron 87, 341–354, July 15, 2015 ª2015 Elsevier Inc. 345
Figure 4. Airway Sensory Neuron Silencing Reduces Lung Inflammation and Hyperresponsiveness
(A–D) OVA-exposedmice develop increasedCD45+ immune cell counts in BALF (A), which include eosinophils (B) and lymphocytes (D), but notmacrophages (C).
(E and F) Silencing lung sensory neurons with QX-314 (100 mM, 72 hr prior to measurement; blue squares) decreased these immune cell responses (A–H).
Representative H&E-stained sections of OVA-exposed lungs treated with saline (E) or QX-314 (100 mM; F) are shown. Scale, 100 mm.
(G and H) Immune cell infiltration severity (G) and basement membrane thickening (H) measured by tissue morphometry in HE sections are shown.
(I and J) HDM challenge increased BALF CD45+ (I) and lymphocyte (J) counts, an effect reversed by QX-314 (100 mM).
(K and L) CFA/OVA sensitization produced a greater increase in Th1/Th2 cell ratio than AlOH/OVA sensitization (K). QX-314 (100 mM) reduced BALF CD45+ cell
counts in the AlOH/OVA-, but not the CFA/OVA-sensitized model (L). Mean ± SEM; two-tailed unpaired Student’s t test (n = 4–25 animals/group, four cohorts).
(M–P) Change in airway reactivity measured as ED200RL (M), resistance (N), and elastance (O) in OVA-exposed mice treated with QX-314 (D–F; 100 mM, day 18) or
saline; difference in vehicle- (***) andOVA-exposed (+++) groups, p < 0.001. OVA-exposedmice performed less voluntary wheel running (P) (1-hr assessment) than
control mice, an effect reversed by QX-314 (100 mM, day 18) assessed 24 hr after silencing. Two-tailed unpaired Student’s t test (n = 4–40 animals/group, two to
three cohorts).Lung Nociceptors Activate ILC2 and Lymphocytes
Lung epithelial and dendritic cells are activated upon an allergen
challenge to stimulate resident lung ILC2 cells (Licona-Limo´n
et al., 2013). ILC2 cells are implicated in the onset of asthma,
and they are directly activated by IL-25 and IL-33 released346 Neuron 87, 341–354, July 15, 2015 ª2015 Elsevier Inc.from goblet and dendritic cells to act upstream of Th2 cells,
B cells, eosinophils, smooth muscle cells, and macrophages.
ILC2 cells produce IL-5, IL-9, and IL-13 and are resident in the
airways, where they orchestrate type 2 immunity (Barnig et al.,
2013; Licona-Limo´n et al., 2013). Activation of ILC2 cells typically
Figure 5. IL-5 Activates NaV1.8
+ Nodose Ganglion Neurons
(A) IL-5 levels in BALFs increased in OVA-challenged mice, an effect reversed by QX-314 (100 mM).
(B) Transcript profiling of naive nodose ganglia reveals basal expression of cytokine receptors including IL-5R.
(C) Cultured nodose ganglion neurons from OVA-exposed mice show a dose-dependent calcium increase in response to IL-5 (0.3–10 mg/ml).
(D) Venn diagram shows overlapping populations of KCL+IL-5+ and AITC- or capsaicin-responsive neurons.
(E and F) IL-5-responsive cells are mainly small and medium sized (E) and nearly null in OVA-exposed NaV1.8-Cre
+/DTA+/ mice (F).
(G) IL-5-mediated calcium increase is absent in 0 external Ca2+.
(H and I) Current-clamp recordings of small cells (capacitance <45 pF) show that IL-5 (1 mg/ml) depolarizes RMP by 6 mV (n = 12 cells).
(J and K) The current needed to trigger an action potential (rheobase) is smaller when IL-5 is present (n = 7 cells). Mean ± SEM; two-tailed unpaired (A–G) and
paired (H–K) Student’s t test (n = 3 biological replicates per group).precedes that of Th2 cells, although transactivation and cooper-
ation occur (Halim et al., 2014; Licona-Limo´n et al., 2013). Typi-
cally activated ILC2 cells produce IL-13 and have higher levels of
the IL-33R, ST2, while a subset of Th2 cells produces IL-5 and IL-
13, the predominant effector cytokines in asthma. We therefore
set out to assess if nociceptor ablation had any effect on ILC2
cell or CD4+ cell activation, as measured by surface markers
and cytokine production. To do this, we examined early immune
changes after two OVA challenges on day 16. Relative to litter-
mate controls (NaV1.8-Cre
/DTA+/), OVA-exposed mice with
ablated nociceptors (NaV1.8-Cre
+/DTA+/) showed decreased
BALF levels of CD45+, as seen previously (Figures 2A and 6A).
In addition, there were fewer CD4+ (Figure 6B) and ILC2 (Fig-
ure 6C) cells. Moreover, nociceptor-ablated mice demonstrated
decreased numbers of IL-13+ ILC2 (Figure 6D) and lower expres-
sion of CD25 (Figure 6E) and ST2 (Figure 6F), ILC2 activationmarkers (Wilhelm et al., 2011). Similarly, QX-314 administration
at the peak of inflammation (100 mM, day 18) reduced the rise
in total CD4+, CD4+IL-5+, and CD4+IL-13+ cells (BALF, on day
21). Thus, both genetic ablation and pharmacologic silencing
of nociceptors result in decreased activation of ILC2s and Th2
effector cytokine production.
Lung Nociceptors Release VIP
The effect of sensory neurons on ILC2 and CD4+ cells likely in-
volves multiple pathways and several candidate neuropeptides
could be involved. Genomic analysis of lung-resident ILC2 cells
has revealed expression of receptors for several neuropeptides
released by sensory neurons, including SP, CGRP, and VIP
(Saenz et al., 2013), providing an opportunity for nociceptors to
directly communicate with these cells. We chose to examine
VIP, both because it is present at high levels in nodose ganglionNeuron 87, 341–354, July 15, 2015 ª2015 Elsevier Inc. 347
Figure 6. Sensory Neurons Control ILC2 and CD4+ Cell Recruitment and Activation in the Lung
(A–F) On day 16, OVA-exposed mice (pink bars) with intact nociceptors (littermate; NaV1.8
/DTA+/) had higher whole-lung CD45+ (A), CD4+ (B), ILC2 (C), ILC2
IL-13+ cell counts (D), as well as ILC2 CD25 (E) and ST2 mean fluorescence intensities (MFIs) (F) than mice with ablated nociceptors (NaV1.8
+/DTA+/).
(G–I) QX-314 treatment (100 mM, day 18; blue squares) decreased OVA-induced CD4+ cells on day 21 (G), including CD4+IL5+ (H) and CD4+IL13+ (I) cells, relative
to control mice (white squares). Mean ± SEM; two-tailed unpaired Student’s t test (n = 4–9 animals/group, one to two cohorts).neurons (Figure 7A) and because its two G protein-coupled re-
ceptors VPAC1 and VPAC2 are expressed by and exert a
powerful regulatory effect on T cells, including differentiation,
migration, and cytokine production (Delgado et al., 2000). We
found that NaV1.8
+ nodose ganglion neurons express VIP (Fig-348 Neuron 87, 341–354, July 15, 2015 ª2015 Elsevier Inc.ure 7B), including lung afferents in OVA-exposed mice (DiI retro-
gradely labeled) (Figure S3A). Cultured nodose ganglion neurons
stimulated with capsaicin (Figure S3B) or IL-5 (Figure 7C)
released VIP, while BALF from OVA-exposed mice contained
elevated VIP compared to vehicle-challenged mice and this
Figure 7. IL-5 Provokes Sensory Neuron Release of VIP to Activate ILC2 and Recruit CD4+ Cells
(A) Gene profiling of naive NaV1.8
+ nodose ganglion neurons reveals expression of nociceptor markers and VIP.
(B) A VIP reporter mouse (VIP-Cre+/EGFP/td-tomato+/ green) reveals that 80% of NaV1.8+ (magenta) nodose ganglion neurons express VIP (green) (scale
bar, 50 mm).
(C) IL-5 (1 hr, 3 mg/ml) induced VIP release from nodose ganglion neurons from OVA-exposed mice.
(D) These mice have elevated BALF VIP levels on day 21 compared to vehicle-exposed mice (white bar), which is decreased by QX-314 treatment (100 mM,
day 18; blue bar).
(E and F) In OVA-exposed lungs, the VPAC2 antagonist PG 99465 (100 nM, every 12 for 48 hr starting on day 16; pink squares) did not impact resident ILC2
numbers (E) but reduced ILC2 activation IL-13+ cells (F).
(G and H) The VPAC2 agonist BAY 55-9837 (10 nM, every 12 for 96 hr; red squares) increased and the VPAC2 antagonist PG 99465 (100 nM, every 12 for 96 hr;
pink squares) decreased CD4+ cell numbers (G) and IL-5 mRNA expression in FACS-sorted CD4+ cells (H). Mean ± SEM; two-tailed unpaired Student’s t test
(n = 3–14 animals/group, one to two cohorts).
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was reduced by inhaled QX-314 (Figure 7D). Nodose ganglions
from OVA-exposed mice expressed more VIP transcripts than
naive mice (data not shown). These data indicate that VIP is
released in the inflamed lung and this can be blocked by
silencing neurons with a charged sodium channel blocker.
VIP Acts on ILC2 and Th2 Cells
We next asked if VIP can act on ILC2 and T cells. We isolated
CD4+ T cells from spleens and lymph nodes of naive mice, and
we differentiated them in vitro under Th1-, Th2-, and Th17-skew-
ing conditions, followed by exposure to VIP. When CD4+ T cells
cultured under Th2-skewing conditions were exposed to recom-
binant mouse VIP (500 nM), their transcript levels of IL-13 (data
not shown) and IL-5 (Figure S3C) increased, suggesting that
VIP contributes to the competence of Th2 cells to transcribe
these type 2 regulatory cytokines. VIP (0–1.0 mM) did not affect
transcription of IL-5 or IL-13 in T cells cultured under Th0-,
Th1-, and Th17-skewing conditions (data not shown). The
VPAC2 antagonist PG 99465 administered early in the OVA chal-
lenge (100 nM in 50 ml, intranasally, every 12 for 48 hr starting on
day 14) significantly decreased CD4+ cells in the whole lung on
day 16, particularly those producing IL-13 (Figures S3D and
S3E). Resident lung ILC2 numbers were not affected by
VPAC2 blockade (Figure 7E), but their activation was signifi-
cantly reduced, as indicated by decreased IL-13 intracellular
staining (Figure 7F) and decreased surface expression of ST2
(Figure S3G). Impaired ILC2 activation may be important given
the key role for this population in the initiation of allergic airway
inflammation (Halim et al., 2014). When the VPAC2 antagonist
was given for a longer period, over the full duration of OVA chal-
lenge (twice daily on days 14–18), it reduced BALF total immune
(CD45+) (Figure S3F) and CD4+ cell numbers (Figure 7G), as well
as IL-5 mRNA expression in CD4+ T cells sorted via fluores-
cence-activated cell sorting (FACS) from BALF on day 19 (Fig-
ure 7H). In contrast, a VPAC1 antagonist did not alter immune
cell number or activation (data not shown). Activation of
VPAC2 in OVA-exposed mice with a selective agonist further
increased CD4+ cell numbers (Figures 7G, S3H, and S3I) and
IL-5 mRNA levels (Figure 7H). VIP signaling through VPAC2
may play, therefore, a significant role in the activation of ILC2
cells and cytokine expression by CD4+ T cells, andmay account,
at least partially, for the ability of nociceptors to amplify type 2
inflammation in the lung.
DISCUSSION
The nervous and immune systems work in concert to protect
against environmental dangers and also can fail together in dis-
ease states, including asthma. Nociceptor-immune interactions
appear to contribute to arthritis-induced inflammation (Levine
et al., 1984), colitis (Engel et al., 2011), psoriasis (Riol-Blanco
et al., 2014), and acute lung injury (Su et al., 2005); however,
the mechanisms by which this happens remain uncertain.
Here we have demonstrated a complex interplay between noci-
ceptors and immune cells. Through pharmacological silencing
and genetic ablation of nociceptors in the OVA- and HDM-
induced mouse models of airway inflammation, we have uncov-
ered a major upstream contribution of these fibers to the350 Neuron 87, 341–354, July 15, 2015 ª2015 Elsevier Inc.generation and persistence of type 2 allergic airway inflamma-
tion and bronchial hyperresponsiveness. Whereas direct
stimulation of lung nociceptors with capsaicin promotes neuro-
peptide release and immune cell infiltration, silencing sensory
neurons or ablation of NaV1.8
+ nociceptors substantially re-
duces immune cell infiltration and bronchial hyperresponsive-
ness. We also have identified a means of communication
between sensory neurons and the select set of immune cells
pivotal for the initiation and amplification of type 2 allergic
inflammation. We found that IL-5, a type 2 effector cytokine
produced by multiple immune cells, directly activates sensory
neurons leading to secretion of the neuropeptide VIP, and
that VIP acts on ILC2 and CD4+ cells to induce cytokine pro-
duction. In addition, we discovered that charged sodium
channel blockers, which specifically and locally silence TRP-
activated sensory neurons, interrupt this signaling loop and
reduce well-established inflammation.
Several studies have suggested that nociceptors play a role in
adaptive immune responses. A reduction in allergic airway
inflammation was shown in TRPA1-KO mice (Caceres et al.,
2009) and upon TRPV1-siRNA knockdown (Mabalirajan et al.,
2013; Rehman et al., 2013), while C-fiber denervation in rats (pro-
duced by neonatal high-dose capsaicin exposure) decreased
OX-6+ dendritic cell numbers in the lung; pulmonary lymphoid
infiltration after allergen challenge (hen egg lysozyme) (Kradin
et al., 1997); and PAR2-mediated airway constriction, pulmonary
inflammation, and edema (Su et al., 2005). Collectively, these
findings, together with studies on atopic dermatitis and psoriasis
(Riol-Blanco et al., 2014; Wilson et al., 2013), indicate that noci-
ceptors can potentiate adaptive immune responses; however,
themechanisms responsible were not identified in these studies.
Here we show that nociceptors are crucial to the generation and
persistence of type 2 airway inflammation, identify a pharmaco-
logical approach for using this insight therapeutically, and
identify some specific mechanisms for these neuro-immune
interactions.
Allergic airway hyperresponsiveness may result both from
local signaling by immune cells directly to airway smooth muscle
cells and through nociceptor-mediated stimulation of sub-
epithelial parasympathetic efferents through central and local
reflexes. A recent study found that ablation of a subset of
TRPV1+ sensory neurons reduced bronchial hyperresponsive-
ness (Tra¨nkner et al., 2014). We replicated this finding using
NaV1.8 ablation, and we extended it by showing similar effects
with the pharmacological silencing of pain fibers, including on
daily voluntary exercise, a new functional readout of airway hy-
perresponsiveness. Tra¨nkner et al. reported that ablation of
TRPV1 sensory neurons did not reverse airway inflammation,
in contrast to our pharmacological and genetic ablation data
that revealed such an effect. Explanations for this discrepancy
include different allergy models (intranasal allergen versus nebu-
lization), timing of measurements (24 versus 96 hr), assessment
methods (Wright-Giemsa stain versus FACS immunophenotyp-
ing), and, most importantly, different targeted neuron popula-
tions (TRPV1 versus NaV1.8). NaV1.8 is expressed byR80% of
nociceptors (Muroi and Undem, 2014) and the majority of
nodose ganglion lung afferents (Kwong et al., 2008), while
TRPV1 is expressed by only 50% of NaV1.8 nociceptors. This
Figure 8. Model of Nociceptor Involvement in Type 2 Inflammation
During allergen exposure, lung afferents are activated by dendritic and epithelial cells. Dendritic cells also polarize precursor Th cells into Th2 cells. Activated
nociceptors release VIP, which stimulates lung-resident ILC2 and newly differentiated Th2 cells via the VPAC2 receptor. Type 2 cytokines, including IL-5 and
IL-13, are released by ILC2 and Th2 cells and initiate the chemotaxis and activation of eosinophils and macrophages, IgE secretion by B cells, mucus production
by goblet cells, and smoothmuscle contraction, culminating in allergic inflammation and bronchial hyperresponsiveness. IL-5 activates nociceptors to trigger VIP
and other neuropeptide release, leading to additional IL-5 production. Scheme inspired by Licona-Limo´n et al. (2013) and Vercelli (2008).suggests that a broad population of nociceptors needs to be
silenced or ablated to interrupt their pro-inflammatory actions.
Th2 and ILC2 cells are both critical to the pathogenesis of
allergic airways disease. We found that after an allergen chal-
lenge in Th2-skewed-sensitized mice, sensory neurons stimu-
late cytokine production in CD4+ and ILC2 cells. ILC2 cells are
implicated in the onset of asthma and are directly activated by
IL-25 and IL-33 released from goblet and dendritic cells, and
they act upstream of Th2 cells, B cells, eosinophils, smoothmus-
cle cells, and macrophages (Walker et al., 2013). Therefore, acti-
vation of sensory neurons on allergen exposure may be a very
early event in igniting inflammation in a sensitized animal. We
asked how sensory neurons may communicate with Th2 and
ILC2 cells to potentiate/initiate inflammation. Activation of noci-
ceptors, through calcium influx, induces the release of neuro-
peptide transmitters from vesicles in the peripheral terminals.
In the lung, release of these neuropeptides occurs in response
to chemical agents (capsaicin, citric acid, nicotine, cigarette
smoke, histamine, and bradykinin) and physical factors (me-
chanical probing, dry gas, and hypertonic aerosols) (Bessac
and Jordt, 2008). Classically, such neuropeptide release (with
a focus on substance P and CGRP) was thought to trigger only
local increased capillary permeability and vasodilation; but, there
have been suggestions that nociceptor-mediated peptide
release may contribute to inflammation in arthritis (Levine et al.,
1984), colitis (Engel et al., 2011), psoriasis (Riol-Blanco et al.,
2014), and acute lung injury (Su et al., 2005). Lung-resident
ILC2 cells express receptors for the sensory neuron neuropep-tide SP, CGRP, and VIP (Saenz et al., 2013). Established neuro-
peptide-mediated immune cell regulation includes the CGRP
and VIP biasing of dendritic cells toward the Th2/Th1 response;
enhanced dendritic cell migration to the lymph node (Ding et al.,
2008); and activation of mast (Ansel et al., 1993), Langerhans
(Hosoi et al., 1993), Th2 cells (Delgado et al., 2000; Ding et al.,
2008), and ILC2 cells (Nussbaum et al., 2013).
Our data suggest that release of VIP by sensory fibers in the
lungactivates ILC2andCD4+Tcells, in addition to their canonical
activation by cytokines, and that this contribution is sufficiently
large that silencing sensory neurons substantially reduces and in-
creases resolution of allergic inflammation (Figure 8). The action
of VIP on immune cells is context and cell type dependent. Unsti-
mulated Th cells have high basal expression of VPAC1 (Harmar
et al., 1998). T cell antigen receptor stimulation, however, upregu-
lates VPAC2 and diminishes VPAC1 expression, and, in con-
sequence, VPAC2 is the dominant transducer of VIP’s effects
on Th2 cells (Lara-Marquez et al., 2001). This shift from
VPAC1 to VPAC2 in activated T cells shifts the balance from
the delayed-type cellular-protective hypersensitivity responses
mediated by Th1 cells to the immediate-type allergic immune re-
sponses mediated by Th2 cells. Supporting a role for VPAC2
signaling in type 2 immune responses, transgenic mice with
high constitutive VPAC2 expression in T cells show blood
eosinophilia, elevated serum IgE levels, greater IgE antibody
responses, and cutaneous immediate-type reactions to allergy-
producing antigens (Voice et al., 2001), while VPAC2-KO mice
showTh1-associated responses (Goetzl et al., 2001). NociceptorNeuron 87, 341–354, July 15, 2015 ª2015 Elsevier Inc. 351
activation and consequent VIP release may elicit, therefore,
different types of immune activation, depending on immune cell
state. Activation of ILC2 cells by VIP results in IL-5 induction
(Nussbaum et al., 2013), something we reproduced here. We
further showed that ILC2 activation in the OVA model of airway
allergic inflammation is reduced by a VPAC2 antagonist. How-
ever, because of the bronchodilator actions of VIP on smooth
muscle (Linde´n et al., 2003), it is unlikely that VPAC2 antagonists
could be used therapeutically for asthma.
What may lead to nociceptor activation after an allergen chal-
lenge? Because nodose ganglion neurons express awide variety
of receptors for many cytokines and chemokines upregulated in
asthma, we explored the possibility that select mediators could
drive nociceptor activation, and we found that IL-5 directly acti-
vates nociceptors, leading to calcium influx and release of VIP,
which act on immune cells to trigger more IL-5 production.
IL-5 is known to be central to asthma-associated pathologies
where it promotes eosinophil recruitment and triggers release
of eosinophil cationic protein (ECP) and transforming growth fac-
tor b (TGF-b) to induce airway smooth muscle inflammation and
hyperreactivity (Shi et al., 1998).
We have uncovered a positive feedforward loop, involving
IL-5, nociceptors, VIP, ILC2, and Th2 cells, that amplifies
type 2 inflammation (Figure 8). There may well be additional
mechanisms to activate sensory neurons during such inflamma-
tion, for example, thymic stromal lymphopoeitin (TSLP), which is
implicated in asthma (Gauvreau et al., 2014). TSLP is released
from keratinocytes in a mouse model of atopic dermatitis to
directly activate a subset of TRPA1+ sensory neurons (as well
as immune cells) to trigger itch (Wilson et al., 2013). Furthermore,
in psoriasis-like conditions, skin allergen-sensitized dendritic
cells make direct contact with afferent sensory neurons and acti-
vate them (Riol-Blanco et al., 2014), although the mediator
responsible is not yet identified.
Currently, there is no treatment that accelerates the resolution
of inflammation in asthma (Levy et al., 2012). Several drugs con-
trol disease symptoms and help abort attacks (Fanta, 2009).
Bronchodilators, b2-agonists, or anti-cholinergics give immedi-
ate relief through relaxation of smooth airway muscle (Green
et al., 2003). Immune modulators inhibit inflammation, with cor-
ticosteroids the primary treatment modality (Green et al.,
2003); however, chronic steroid use leads to adverse effects
(Locksley, 2010). Despite the effectiveness of current therapy
for mild asthma, patients with severe asthma have frequent ex-
acerbations and excess morbidity. Asthma is a heterogeneous
condition, but a therapeutic approach that targets nociceptors
upstream of type 2 inflammation might provide a broadly effec-
tive treatment for many patients (Barnes, 2004). Nevertheless,
sensory neuron interaction with immune cells appears to be
highly cell and context dependent; for example, during pathogen
invasion, the release of neuropeptides (CGRP, galanin, and so-
matostatin) suppresses innate immune responses (Chiu et al.,
2013), in contrast to the amplifying role we report here for
type 2 allergic airway inflammation, and treatment would need
to be evaluated and individualized accordingly.
In conclusion, the silencing and genetic ablation of nocicep-
tors has uncovered amajor upstream contribution of these fibers
in the generation and persistence of type 2 allergic airway inflam-352 Neuron 87, 341–354, July 15, 2015 ª2015 Elsevier Inc.mation and bronchial hyperresponsiveness. Sensory neurons,
upon activation by allergen exposure in sensitized animals, con-
trol through local neuropeptide release at their peripheral termi-
nals type 2 inflammation, acting on ILC2 and CD4+ cells. These
cells secrete cytokines such as IL-5 that recruit effector immune
cells integral to the disease state, and also further activate sen-
sory neurons. Silencing sensory neurons provides, therefore, a
potential strategy worth exploring for the treatment of type 2
allergies, potentially including conjunctivitis, rhinitis, and asthma.
This strategy is highly specific, only targeting neurons whose
TRP channels are activated by inflammation, with expected
low systemic side effects (positively charged drugs have limited
capability of spreading) and a long duration of action (positively
charged compounds should remain trapped inside neurons for
prolonged periods), constituting a novel therapeutic approach
to allergic airway inflammation centered on interrupting sensory
neuron immune signaling.
EXPERIMENTAL PROCEDURES
All procedures were approved by the Institutional Animal Care and Use Com-
mittees of Boston Children’s Hospital. Allergic airway inflammation was
studied in an OVA-based model (Haworth et al., 2008). On days 0 and 7,
mice were sensitized by 200-ml-i.p. injections of a solution containing
1 mg/ml OVA (Sigma-Aldrich) and 5 mg/ml aluminum hydroxide (Sigma-
Aldrich). On days 14–17 (10:00 am), mice were exposed to 6% OVA aerosol
for 25 min. QX-314 (100 mM) was nebulized on day 18, mice were sacrificed
on day 21, and BALF was harvested; cells were isolated, counted, and immu-
nophenotyped using FACS.We also investigated the impact of sensory neuron
silencing in a Th1-skewedmodel of allergic airway inflammation (Bogaert et al.,
2011) following subcutaneous (s.c.) sensitization with OVA (1 mg/ml) in a
200-ml emulsion of sterile PBS and 50% CFA on day 0 and with 50% incom-
plete Freund’s adjuvant (IFA) on day 7. Another type 2 inflammation model
was induced by HDM (Johnson et al., 2004). Lightly anesthetized (isoflurane)
mice were sensitized (days 1–5) and challenged (days 8–10) with HDM
(25 mg/10 ml, intranasally) and exposed to QX-314 (100 mM, day 12). Mice
were sacrificed on day 15 and BALF was harvested; cells were isolated,
counted, and immunophenotyped using FACS.
Statistics
Data are expressed as mean ± SEM from 4–36 mice. Statistical significance
determined by two-tail (unpaired or paired [patch-clamp]) Student’s t test;
p values less than 0.05 were considered significant. Numbers of animals are
defined in figure legends.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.neuron.2015.06.007.
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